Company’s 36-month beta value is 1.64.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for PSTX is 67.28M, and currently, short sellers hold a 6.85% ratio of that floaft. The average trading volume of PSTX on December 03, 2024 was 1.02M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PSTX) stock’s latest price update
Poseida Therapeutics Inc (NASDAQ: PSTX) has seen a rise in its stock price by 0.11 in relation to its previous close of 9.31. However, the company has experienced a 241.39% gain in its stock price over the last five trading sessions. zacks.com reported 2024-11-28 that From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX’s 50-day simple moving average crossed above its 200-day simple moving average, which is known as a “golden cross” in the trading world.
PSTX’s Market Performance
PSTX’s stock has risen by 241.39% in the past week, with a monthly rise of 293.25% and a quarterly rise of 225.87%. The volatility ratio for the week is 2.37% while the volatility levels for the last 30 days are 8.67% for Poseida Therapeutics Inc The simple moving average for the last 20 days is 120.77% for PSTX stock, with a simple moving average of 204.02% for the last 200 days.
Analysts’ Opinion of PSTX
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PSTX reach a price target of $15. The rating they have provided for PSTX stocks is “Buy” according to the report published on January 04th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to PSTX, setting the target price at $24 in the report published on January 07th of the previous year.
PSTX Trading at 186.43% from the 50-Day Moving Average
After a stumble in the market that brought PSTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.06% of loss for the given period.
Volatility was left at 8.67%, however, over the last 30 days, the volatility rate increased by 2.37%, as shares surge +277.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +176.56% upper at present.
During the last 5 trading sessions, PSTX rose by +241.39%, which changed the moving average for the period of 200-days by +151.89% in comparison to the 20-day moving average, which settled at $4.22. In addition, Poseida Therapeutics Inc saw 177.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PSTX starting from Gergen Mark J, who sale 30,000 shares at the price of $9.27 back on Nov 26 ’24. After this action, Gergen Mark J now owns 651,291 shares of Poseida Therapeutics Inc, valued at $278,100 using the latest closing price.
MARK GERGEN, the Director of Poseida Therapeutics Inc, proposed sale 120,000 shares at $2.86 during a trade that took place back on Nov 26 ’24, which means that MARK GERGEN is holding shares at $343,200 based on the most recent closing price.
Stock Fundamentals for PSTX
Current profitability levels for the company are sitting at:
- -0.41 for the present operating margin
- 0.95 for the gross margin
The net margin for Poseida Therapeutics Inc stands at -0.39. The total capital return value is set at -0.29. Equity return is now at value -57.63, with -20.39 for asset returns.
Based on Poseida Therapeutics Inc (PSTX), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at 0.68. The interest coverage ratio of the stock is -6.89.
Currently, EBITDA for the company is -109.04 million with net debt to EBITDA at -0.72. When we switch over and look at the enterprise to sales, we see a ratio of 6.24. The receivables turnover for the company is 10.23for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.20.
Conclusion
In a nutshell, Poseida Therapeutics Inc (PSTX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
